Biography
I conduct clinical research on a variety of gastrointestinal cancers and provide care for patients with those cancers. We have trials of combined modality therapy (surgery +/- radiation +/- chemotherapy) on gastric, esophageal, pancreas and rectal cancers. We also perform phase I and II trials of biologically targeted agents as well as newer immunotherapeutics. In collaboration with a number of colleagues, we conduct translational studies analyzing novel imaging (e.g. contrast enhanced ultrasound and perfusion scans) and molecular biomarkers (e.g. CDX2 as a prognostic and predictive factor in colon cancer and matrix metalloproteinases as prognostic factors in pancreas cancer). Neuroendocrine tumors, pancreas, colorectal and gastro-esophageal cancers have been areas of particular research focus with multiple therapeutic and translational studies devote to each. Examples of recently completed trials include a randomized phase III trial of a vaccine (algenpantucel) for resected pancreas cancer, phase Ib trial of anti-PD-L1 and separate phase II trials using PD-1 antibody for tumors with micro satellite instability and chemotherapy with angiogenesis inhibitors for advanced neuroendocrine tumors and gastro-esophageal adenocarcinomas. Currently active areas of study include combining immunomodulating antibodies in combination therapy and randomized phase II colon cancer trials of an antibody to interleukin 1 or a first in class agent known as RadioRx. Participation and leadership in NCI cooperative group protocols gives our patients access to the randomized trials that hope to establish new standards of care for a variety of GI cancers.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Medical Oncology (2024)
- Medical Education: Stanford University School of Medicine (1987) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (1993) CA
-
- Residency: Stanford University Internal Medicine Residency (1989) CA
- Internship: Stanford University Internal Medicine Residency (1988) CA
- BS, Stanford University, Biology (1976)
- PhD, Stanford University, Cancer Biology (1987)
- MD, Stanford University, Medicine (1987)
- Residency, Stanford University, Internal Medicine (1989)
- Fellowship, Stanford University, Medical Oncology (1993)
Memberships
- Chair, 2020 GI Symposium Steering Committee (2019 - Present)
- Co-Chair Scientific Advisory Board, Neuroendocrine Tumor Research Foundation (2011 - Present)
- member, NCI GI Steering Committee, National Cancer Institute (2017 - Present)
-
- Member, Scientific and Medical Advisory Board, Pancreatic Cancer Action Network (2012 - Present)
- Vice Chair; GI Committee, ECOG/ACRIN (2015 - Present)
Administrative Appointments
- Director, Cancer Clinical Trials Office (2004 - 2013)
- Physician Leader, GI Clinical Research Group (2010 - 2015)
- Physician Leader, GI Oncology Disease Management Group (2011 - 2015)
-
- Vice Chair GI Committee, ECOG-ACRIN (2015 - Present)
Publications
-
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., Kwoh, T. J., … Sikic, B. I. (1999). Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. CLINICAL CANCER RESEARCH, 5(11), 3357–3363. -
Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance
Lum, B. L., Kaubisch, S., Fisher, G. A., Brown, B. W., & Sikic, B. I. (2000). Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 45(4), 305–311. -
Pancreatic tumors show high levels of hypoxia
Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A., Terris, D. J., Brown, J. M., … Vierra, M. (2000). Pancreatic tumors show high levels of hypoxia. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(4), 919–22. -
-
Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer
Mehta, V. K., Fisher, G. A., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., & Poen, J. C. (2000). Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(5), 1483–87. -
Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report
Mehta, V. K., Fisher, G. A., Ford, J. M., Poen, J. C., Vierra, M. A., Oberhelman, H. A., & Bastidas, A. J. (2001). Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report. ARCHIVES OF SURGERY, 136(1), 65–69. -
Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis
Lai, K. M., MILLAN, M., Razavi, M., Keeffe, E. B., Prapong, W., Fisher, G. A., … So, S. K. S. (2001). Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis. TRANSPLANTATION PROCEEDINGS, 33(1-2), 1490–91. -
Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas
Mehta, V. K., Fisher, G., Ford, J. A., Poen, J. C., Vierra, M. A., Oberbelman, H., … Bastidas, J. A. (2001). Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. JOURNAL OF GASTROINTESTINAL SURGERY, 5(1), 27–35. -
Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer
Mehta, V. K., Poen, J. C., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., & Fisher, G. A. (2001). Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 24(2), 155–59. -
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., & Sikic, B. I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. CLINICAL CANCER RESEARCH, 7(5), 1221–29. -
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
Fong, L., Hou, Y. F., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., … Engleman, E. G. (2001). Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 98(15), 8809–14. -
Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer
Mehta, V. K., Poen, J., Ford, J., Edelstein, P. S., Vierra, M., Bastidas, A. J., … Fisher, G. (2001). Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. DISEASES OF THE COLON & RECTUM, 44(1), 52–58. -
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer
Mehta, V. K., Cho, C., Ford, J. M., Jambalos, C., Poen, J., Koong, A., … Fisher, G. (2003). Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 55(1), 132–37. -
PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE
Yahanda, A. M., ADLER, K. M., Fisher, G. A., BROPHY, N. A., Halsey, J., Hardy, R. I., … Sikic, B. I. (1992). PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 10(10), 1624–1634. -
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies
Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., Cohen, M., … Sikic, B. I. (2003). Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. CLINICAL CANCER RESEARCH, 9(14), 5187–94. -
A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma
Advani, R., Peethambaram, P., Lum, B. L., Fisher, G. A., Hartmann, L., Long, H. J., … Sikic, B. I. (2004). A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. CANCER, 100(2), 321–26. -
Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer
Koong, A. C., Le, Q. T., Ho, A., Fong, B., Fisher, G., Cho, C., … Bastidas, J. A. (2004). Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(4), 1017–21. -
Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma
Lin, A. Y., Brophy, N., Fisher, G. A., So, S., Biggs, C., Yock, T. I., & Levitt, L. (2005). Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. CANCER, 103(1), 119–25. -
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer
Wakelee, H., & Fisher, G. A. (2005). A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. INVESTIGATIONAL NEW DRUGS, 23(3), 241–42. -
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., Ford, J. M., … Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613–19. -
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., & Sikic, B. I. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ANNALS OF ONCOLOGY, 16(12), 1968–73. -
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., Holmlund, J. T., … Sikic, B. I. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 467–77. -
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer
Koong, A. C., Christofferson, E., Le, Q. T., Goodman, K. A., Ho, A., Kuo, T., … Yang, G. P. (2005). Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(2), 320–23. -
Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
Kuo, T., & Fisher, G. A. (2005). Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. Clinical Colorectal Cancer, 5, S62–70. -
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
Cho, C. D., Fisher, G. A., Halsey, J., & Sikic, B. I. (2006). Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. INVESTIGATIONAL NEW DRUGS, 24(2), 117–23. -
Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer
Street, H. H., Goris, M. L., Fisher, G. A., Wessels, B. W., Cho, C., Hernandez, C., … Knox, S. J. (2006). Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 21(3), 243–56. -
Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer
Cabebe, E., & Fisher, G. A. (2007). Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 16(4), 467–76. -
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
Demetri, G. D., Benjamin, R. S., Blanke, C. D., Blay, J.-Y., Casali, P., Choi, H., … Zalcberg, J. (2007). NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. Journal of the National Comprehensive Cancer Network , 5, S1–29. -
Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies
Cupp, J. S., Koong, A. C., Fisher, G. A., NORTON, J. A., & Goodman, K. A. (2008). Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies. CLINICAL ONCOLOGY, 20(1), 69–75. -
Phase H study of imatinib in unresectable hepatocellular carcinoma
Lin, A. Y., Fisher, G. A., So, S., Tang, C., & Levitt, L. (2008). Phase H study of imatinib in unresectable hepatocellular carcinoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 31(1), 84–88. -
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer
Schellenberg, D., Goodman, K. A., Lee, F., Chang, S., Kuo, T., Ford, J. M., … Koong, A. C. (2008). Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(3), 678–86. -
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613–1618. -
A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer
Fischer, G. A., Kuo, T., Ramsey, M., Schwartz, E., Rouse, R. V., Cho, C. D., … Sikic, B. I. (2008). A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer. CLINICAL CANCER RESEARCH, 14(21), 7074–79. -
Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas
Chang, D. T., Schellenberg, D., Shen, J., Kim, J., Goodman, K. A., Fisher, G. A., … Koong, A. C. (2009). Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas. CANCER, 115(3), 665–72. -
Impaired interferon signaling is a common immune defect in human cancer
Critchley-Thorne, R. J., Simons, D. L., Yan, N., Miyahira, A. K., Dirbas, F. M., Johnson, D. L., … Lee, P. P. (2009). Impaired interferon signaling is a common immune defect in human cancer. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(22), 9010–15. -
Pathological response after chemoradiation for T3 rectal cancer.
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., … Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. Colorectal Disease , 12(7 Online), e24–30. -
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., Miceli, R., … Tolcher, A. W. (2010). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. ANNALS OF ONCOLOGY, 21(2), 376–81. -
Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., Kunz, P., … Chang, D. T. (2010). Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. DISEASES OF THE ESOPHAGUS, 23(4), 300–308. -
Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis
Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., Fisher, G. A., … Koong, A. C. (2009). Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. JOURNAL OF TRANSLATIONAL MEDICINE, 7. -
(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY
Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., Ford, J. M., … Chang, D. T. (2010). (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(5), 1420–25. -
Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies
Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., Losa, R., … Sikic, B. I. (2011). Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies. INVESTIGATIONAL NEW DRUGS, 29(5), 971–77. -
Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer
Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., Ford, J. M., … Chang, D. T. (2010). Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer. CANCER. CHICAGO,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL: JOHN WILEY & SONS INC. -
Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma
Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., Kunz, P., … Pai, R. K. (2010). Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma. CANCER. CHICAGO,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL: WILEY-BLACKWELL. -
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
Kulke, M. H., Siu, L. L., Tepper, J. E., Fisher, G., Jaffe, D., Haller, D. G., … Yao, J. C. (2011). Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 934–943. -
Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal
Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., Fisher, G. A., … Chang, D. T. (2011). Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. CANCER, 117(15), 3342–51. -
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Cabebe, E. C., Fisher, G. A., & Sikic, B. I. (2012). A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. INVESTIGATIONAL NEW DRUGS, 30(3), 1082–87. -
F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases
Zissen, M. H., Kunz, P., Subbarayan, M., Chin, F. T., Conti, P. S., Fisher, G. A., & Quon, A. (2011). F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. NUCLEAR MEDICINE COMMUNICATIONS, 32(5), 343–47. -
HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., Balise, R. R., … Pai, R. K. (2012). HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(1), 13–24. -
Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection
Norton, J. A., Harris, E. J., Chen, Y., Visser, B. C., Poultsides, G. A., Kunz, P. C., … Jensen, R. T. (2011). Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection. ARCHIVES OF SURGERY, 146(6), 724–32. -
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
Kunz, P. L., & Fisher, G. A. (2010). Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical and Experimental Gastroenterology, 3, 79–86. -
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., Pedro-Salcedo, M. S., … Wakelee, H. A. (2012). A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(4), 1013–20. -
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., Ford, J. M., … Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. CHICAGO,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL: ELSEVIER SCIENCE INC. -
Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis
Poultsides, G. A., Huang, L. C., Chen, Y., Visser, B. C., Pai, R. K., Jeffrey, R. B., … Norton, J. A. (2012). Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2295–2303. -
Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features
Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., Jayachandran, P., … Pai, R. K. (2012). Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. MODERN PATHOLOGY, 25(8), 1128–39. -
Capecitabine-Induced Chest Pain Relieved by Diltiazem
Ambrosy, A. P., Kunz, P. L., Fisher, G. A., & Witteles, R. M. (2012). Capecitabine-Induced Chest Pain Relieved by Diltiazem. AMERICAN JOURNAL OF CARDIOLOGY, 110(11), 1623–26. -
Long-Term Survivors of Gastric Cancer: A California Population-Based Study
Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., & Clarke, C. A. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. JOURNAL OF CLINICAL ONCOLOGY, 30(28), 3507–15. -
Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?
Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., Kunz, P. L., … Poultsides, G. A. (2013). Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? ANNALS OF SURGICAL ONCOLOGY, 20(5), 1631–38. -
Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors Consensus Results From a Modified Delphi Process
Strosberg, J. R., Fisher, G. A., Benson, A. B., Malin, J. L., Cherepanov, D., & Broder, M. S. (2013). Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors Consensus Results From a Modified Delphi Process. PANCREAS, 42(3), 397–404. -
DNA DAMAGE DOES NOT APPEAR TO BE A TRIGGER FOR THERMOTOLERANCE IN MAMMALIAN-CELLS
Anderson, R. L., Shiu, E., Fisher, G. A., & Hahn, G. M. (1988). DNA DAMAGE DOES NOT APPEAR TO BE A TRIGGER FOR THERMOTOLERANCE IN MAMMALIAN-CELLS. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 54(2), 285–98. -
CORRELATION OF MAMMALIAN-CELL KILLING BY HEAT-SHOCK TO INTRAMEMBRANOUS PARTICLE AGGREGATION AND LATERAL PHASE-SEPARATION USING FLUORESCENCE-ACTIVATED CELL SORTING
RICE, G. C., Fisher, K. A., Fisher, G. A., & Hahn, G. M. (1987). CORRELATION OF MAMMALIAN-CELL KILLING BY HEAT-SHOCK TO INTRAMEMBRANOUS PARTICLE AGGREGATION AND LATERAL PHASE-SEPARATION USING FLUORESCENCE-ACTIVATED CELL SORTING. RADIATION RESEARCH, 112(2), 351–64. -
Drug resistance in clinical oncology and hematology. Introduction.
Fisher, G. A., & Sikic, B. I. (1995). Drug resistance in clinical oncology and hematology. Introduction. Hematology/Oncology Clinics of North America, 9(2), xi-xii. -
CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE
Fisher, G. A., & Sikic, B. I. (1995). CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 9(2), 363–382. -
Clinical reversal of multidrug resistance.
Sikic, B. I., Fisher, G. A., Lum, B. L., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., & Halsey, J. (1994). Clinical reversal of multidrug resistance. Cancer Treatment and Research, 73, 149–165. -
CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., Kaubisch, S., … Sikic, B. I. (1993). CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS. CANCER, 72(11), 3502–3514. -
MAMMALIAN-CELL SURVIVAL STUDIES CHARACTERIZING MULTIPORT NEGATIVE PI-MESON IRRADIATION WITH THE STANFORD MEDICAL PION GENERATOR (SMPG)
Li, G. C., Fessenden, P., Hahn, G. M., Fisher, G., Luxton, G., & Bagshaw, M. A. (1994). MAMMALIAN-CELL SURVIVAL STUDIES CHARACTERIZING MULTIPORT NEGATIVE PI-MESON IRRADIATION WITH THE STANFORD MEDICAL PION GENERATOR (SMPG). INTERNATIONAL JOURNAL OF HYPERTHERMIA, 10(3), 361–70. -
PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE
Bartlett, N. L., Lum, B. L., Fisher, G. A., BROPHY, N. A., EHSAN, M. N., Halsey, J., & Sikic, B. I. (1994). PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 12(4), 835–42. -
REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY
LEYLANDJONES, B., Dalton, W., Fisher, G. A., & Sikic, B. I. (1993). REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY. CANCER, 72(11), 3484–3488. -
The reversal of multidrug resistance.
Fisher, G. A., Lum, B. L., & Sikic, B. I. (1995). The reversal of multidrug resistance. Cancer Treatment and Research, 78, 45–70. -
Pharmacological considerations in the modulation of multidrug resistance
Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996). Pharmacological considerations in the modulation of multidrug resistance. EUROPEAN JOURNAL OF CANCER, 32A(6), 1082–1088. -
Clinical decision making based on radionuclide determined ejection fraction in oncology patients
Peng, N. J., Advani, R., Kopiwoda, S., Fisher, G., & Strauss, H. W. (1997). Clinical decision making based on radionuclide determined ejection fraction in oncology patients. JOURNAL OF NUCLEAR MEDICINE, 38(5), 702–5. -
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
Sikic, B. I., Fisher, G. A., Lum, B. L., Halsey, J., BEKETICORESKOVIC, L., & Chen, G. (1997). Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Presented at the 12th Bristol-Myers-Squibb Nagoya International Cancer Treatment Symposium, NAGOYA,JAPAN: SPRINGER. -
Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil
Poen, J. C., Collins, H. L., Niederhuber, J. E., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., … Goffinet, D. R. (1998). Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 40(1), 93–99. -
Liver transplantation for hepatocellular carcinoma and the role of preoperative chemoembolization.
Millan, M. T., Lai, K. M., Keeffe, E. B., Fisher, G. A., Razavi, M. K., Prapong, W., … So, S. K. S. (2000). Liver transplantation for hepatocellular carcinoma and the role of preoperative chemoembolization. TRANSPLANTATION, 69(8), S215–S215. -
Pathological response after chemoradiation for T3 rectal cancer
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., … Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. COLORECTAL DISEASE, 12(7), E24–E30. -
A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies
Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., Lum, B. L., & Sikic, B. I. (2002). A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies. Presented at the 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, FRANKFURT,GERMANY: ELSEVIER SCI LTD. -
A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.
Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., … Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S–6103S. -
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound staged T3 rectal cancer
Mehta, V. K., Poen, J. C., Ford, J., Young, H., Cho, C., & Fisher, G. (2001). Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound staged T3 rectal cancer. CANCER JOURNAL, 7(6), 539–539. -
The Stanford experience with preoperative chemoradiation using CPT-11 and 5-FU in locally advanced rectal cancer: Toxicities and outcomes
Tillman, G. F., Fisher, G., Cho, C., Ford, J. M., Mehta, V. K., Welton, M., … Koong, A. (2004). The Stanford experience with preoperative chemoradiation using CPT-11 and 5-FU in locally advanced rectal cancer: Toxicities and outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60(1), S417–S418. -
Phase I study of I-131-chimeric(ch) TNT-1/B antibody for the treatment of advanced colorectal cancer
Knox, S., Fisher, G., Wessels, B., Cho, C., Hernandez, M. C., Street, H., … Goris, M. (2004). Phase I study of I-131-chimeric(ch) TNT-1/B antibody for the treatment of advanced colorectal cancer. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 19(4), 528–28. -
The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin.
Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., Halsey, J., & Sikic, B. I. (2002). The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. CLINICAL PHARMACOLOGY & THERAPEUTICS, 71(2), P48–P48. -
Medical treatment consensus in unresectable midgut gastrointestinal neuroendocrine tumors.
Strosberg, J. R., Fisher, G. A., Benson, A. B., Malin, J. L., Anthony, L. B., Arslan, B., … Broder, M. S. (2012). Medical treatment consensus in unresectable midgut gastrointestinal neuroendocrine tumors. JOURNAL OF CLINICAL ONCOLOGY, 30(15). -
THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD
Fisher, G. A., BROPHY, N. A., Yahanda, A. M., Adler, K. A., Lum, B. L., Bartlett, N. L., … Sikic, B. I. (1993). THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD. Presented at the INTERNATIONAL SYMP ON THE MECHANISM AND NEW APPROACH ON DRUG RESISTANCE OF CANCER CELLS, SAPPORO,JAPAN: ELSEVIER SCIENCE PUBL B V. -
INDUCTION OF THERMOTOLERANCE AND EVIDENCE FOR A WELL-DEFINED, THERMOTROPIC COOPERATIVE PROCESS
Li, G. C., Fisher, G. A., & Hahn, G. M. (1982). INDUCTION OF THERMOTOLERANCE AND EVIDENCE FOR A WELL-DEFINED, THERMOTROPIC COOPERATIVE PROCESS. RADIATION RESEARCH, 89(2), 361–368. -
MODIFICATION OF THE THERMAL RESPONSE BY D2O .1. CELL-SURVIVAL AND THE TEMPERATURE SHIFT
Fisher, G. A., Li, G. C., & Hahn, G. M. (1982). MODIFICATION OF THE THERMAL RESPONSE BY D2O .1. CELL-SURVIVAL AND THE TEMPERATURE SHIFT. RADIATION RESEARCH, 92(3), 530–540. -
MODIFICATION OF THE THERMAL RESPONSE BY D2O .2. THERMOTOLERANCE AND THE SPECIFIC-INHIBITION OF DEVELOPMENT
Li, G. C., Fisher, G. A., & Hahn, G. M. (1982). MODIFICATION OF THE THERMAL RESPONSE BY D2O .2. THERMOTOLERANCE AND THE SPECIFIC-INHIBITION OF DEVELOPMENT. RADIATION RESEARCH, 92(3), 541–551. -
Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors
Qadan, M., Ma, Y., Visser, B. C., Kunz, P. L., Fisher, G. A., Norton, J. A., & Poultsides, G. A. (2014). Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 218(2), 188–95. -
Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.
Worhunsky, D. J., Krampitz, G. W., Poullos, P. D., Visser, B. C., Kunz, P. L., Fisher, G. A., … Poultsides, G. A. (2014). Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB , 16(4), 304–11. -
Symptoms and palliative care needs of pancreatic adenocarcinoma patients.
Luo, J., Chen, J. J., Deguzman, C., Mustian, K., Insco, M., Fisher, G., & Palesh, O. (2014). Symptoms and palliative care needs of pancreatic adenocarcinoma patients. Journal of Palliative Medicine, 17(6), 640–41. -
Limitations of Body Surface Area-Based Activity Calculation for Radioembolization of Hepatic Metastases in Colorectal Cancer
Lam, M. G. E. H., Louie, J. D., Abdelmaksoud, M. H. K., Fisher, G. A., Cho-Phan, C. D., & Sze, D. Y. (2014). Limitations of Body Surface Area-Based Activity Calculation for Radioembolization of Hepatic Metastases in Colorectal Cancer. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 25(7), 1085–93. -
Limitations of body surface area-based activity calculation for radioembolization of hepatic metastases in colorectal cancer.
Lam, M. G. E. H., Louie, J. D., Abdelmaksoud, M. H. K., Fisher, G. A., Cho-Phan, C. D., & Sze, D. Y. (2014). Limitations of body surface area-based activity calculation for radioembolization of hepatic metastases in colorectal cancer. Journal of Vascular and Interventional Radiology , 25(7), 1085–93. -
Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., … Chang, D. T. (2014). Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90(4), 918–25. -
Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
Herman, J. M., Chang, D. T., Goodman, K. A., Dholakia, A. S., Raman, S. P., Hacker-Prietz, A., … Koong, A. C. (2015). Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma. CANCER, 121(7), 1128–37. -
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., BARTLETT, B. R., Kemberling, H., Eyring, A. D., … Diaz, L. A. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. NEW ENGLAND JOURNAL OF MEDICINE, 372(26), 2509–20. -
Randomized Phase 2 Study of Pegylated SN-38 (EZN-2208) or Irinotecan Plus Cetuximab in Patients With Advanced Colorectal Cancer
Garrett, C. R., Bekaii-Saab, T. S., Ryan, T., Fisher, G. A., Clive, S., Kavan, P., … Goldberg, R. M. (2013). Randomized Phase 2 Study of Pegylated SN-38 (EZN-2208) or Irinotecan Plus Cetuximab in Patients With Advanced Colorectal Cancer. CANCER, 119(24), 4223–4230. -
Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity.
Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., … Chang, D. T. (2014). Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. International Journal of Radiation Oncology, Biology, Physics, 90(4), 918–25. -
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Dalerba, P., Sahoo, D., Paik, S., Guo, X., Yothers, G., Song, N., … Clarke, M. F. (2016). CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 374(3), 211–22. -
Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.
Cloyd, J. M., Kopecky, K. E., Norton, J. A., Kunz, P. L., Fisher, G. A., Visser, B. C., … Poultsides, G. A. (2016). Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. Surgery, 160(3), 708–13. -
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik, A. I., Wolin, E. M., Liyanage, N., Gomez-Panzani, E., & Fisher, G. A. (2016). EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Endocrine Practice , 22(9), 1068–1080. -
Perspectives on clinical trials for gastrointestinal malignancies.
Eng, C., Roach, N., Longabaugh, M., & Fisher, G. (2015). Perspectives on clinical trials for gastrointestinal malignancies. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 40–43. -
Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.
Rao, A. D., Sugar, E. A., Chang, D. T., Goodman, K. A., Hacker-Prietz, A., Rosati, L. M., … Herman, J. M. (2016). Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Practical Radiation Oncology, 6(6), 417–24. -
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
Kunz, P. L., Balise, R. R., Fehrenbacher, L., Pan, M., Venook, A. P., Fisher, G. A., … Bergsland, E. K. (2016). Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas, 45(10), 1394–1400. -
Reduced dose CT with model-based iterative reconstruction compared to standard dose CT of the chest, abdomen, and pelvis in oncology patients: intra-individual comparison study on image quality and lesion conspicuity.
Morimoto, L. N., Kamaya, A., Boulay-Coletta, I., Fleischmann, D., Molvin, L., Tian, L., … Willmann, J. K. (2017). Reduced dose CT with model-based iterative reconstruction compared to standard dose CT of the chest, abdomen, and pelvis in oncology patients: intra-individual comparison study on image quality and lesion conspicuity. Abdominal Radiology . -
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
Scicinski, J., Fisher, G., Carter, C., Cho-Phan, C., Kunz, P., Ning, S., … Reid, T. (2015). The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Redox Biology, 5, 422-? -
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
Hege, K. M., Bergsland, E. K., Fisher, G. A., Nemunaitis, J. J., Warren, R. S., McArthur, J. G., … Sherwin, S. A. (2017). Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. Journal for Immunotherapy of Cancer, 5, 22-? -
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Kunz, P. L., Catalano, P. J., Nimeiri, H. S., Fisher, G. A., Longacre, T. A., Schrijver, I., … Benson, A. B. (2015). A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
A first-in-class, first-in-human Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
Sikic, B. (2018). A first-in-class, first-in-human Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors. 2018 ASCO Annual Meeting (June 1-5, 2018): American Society of Clinical Oncology. -
A Phase 1b/2 Study of CD40 Agonistic Monoclonal Antibody (APX005M) Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Adenocarcinoma Patients.
O'Hara, M., O'Reilly, E., Mick, R., Varadhachary, G., Wainberg, Z., Ko, A., … Vonderheide, R. (2018). A Phase 1b/2 Study of CD40 Agonistic Monoclonal Antibody (APX005M) Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Adenocarcinoma Patients. 2018 ASCO Annual Meeting (June 1-5, 2018): American Society of Clinical Oncology. -
Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.
Tummers, W. S., Miller, S. E., Teraphongphom, N. T., Gomez, A., Steinberg, I., Huland, D. M., … Rosenthal, E. L. (2018). Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Annals of Surgical Oncology, 25(7), 1880–88. -
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study
Fisher, G. A., Wolin, E. M., Liyanage, N., Lowenthal, S. P., Mirakhur, B., Pommier, R. F., … Vinik, A. (2018). Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. ONCOLOGIST, 23(1), 16–24. -
Elevated Levels of 5-HIAA and CgA in Patients With Pancreatic Neuroendocrine Tumors (PanNETs): Analyses From the CLARINET Study
Phan, A. T., Wolin, E. M., Liyanage, N., Mirakhur, B., Lowenthal, S. W. P., Vinik, A. I., … Pavel, M. E. (2018). Elevated Levels of 5-HIAA and CgA in Patients With Pancreatic Neuroendocrine Tumors (PanNETs): Analyses From the CLARINET Study. PANCREAS, 47(3), 350–51. -
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAIVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY
Fisher, G. A., Wolin, E. M., Liyanage, N., Lowenthal, S. P., Mirakhur, B., Pommier, R. F., … Vinik, A. I. (2018). LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAIVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY. ENDOCRINE PRACTICE, 24(3), 243–55. -
Change in Patient-Reported Symptom Control in Patients With Neuroendocrine Tumors Treated With Lanreotide Depot
Wolin, E. M., Lowenthal, S. P., Fisher, G. A., Liyanage, N., Mirakhur, B., Pommier, R. F., … Vinik, A. I. (2018). Change in Patient-Reported Symptom Control in Patients With Neuroendocrine Tumors Treated With Lanreotide Depot. PANCREAS, 47(3), 358. -
Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study
Pommier, R. F., Fisher, G. A., Wolin, E. M., Liyanage, N., Lowenthal, S. P., Mirakhur, B., … Vinik, A. I. (2018). Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study. PANCREAS, 47(3), 352. -
5-Hydroxyindoleacetic Acid (5-HIAA) and Chromogranin A (CgA) as Biomarkers Secreted by Neuroendocrine Tumors (NETs): A Pooled Analysis of the ELECT and CLARINET Studies
Fisher, G. A., Vinik, A. I., Pavel, M. E., Phan, A. T., Mirakhur, B., Massien, C., … Pommier, R. F. (2018). 5-Hydroxyindoleacetic Acid (5-HIAA) and Chromogranin A (CgA) as Biomarkers Secreted by Neuroendocrine Tumors (NETs): A Pooled Analysis of the ELECT and CLARINET Studies. PANCREAS, 47(3), 339. -
Quantitative Three-Dimensional Dynamic Contrast-Enhanced Ultrasound Imaging: First-In-Human Pilot Study in Patients with Liver Metastases
El Kaffas, A., Sigrist, R. M. S., Fisher, G., Bachawal, S., Liau, J., Wang, H., … Willmann, J. K. (2017). Quantitative Three-Dimensional Dynamic Contrast-Enhanced Ultrasound Imaging: First-In-Human Pilot Study in Patients with Liver Metastases. THERANOSTICS, 7(15), 3745–58. -
Change in Patient-Reported Symptom Control in Patients With Neuroendocrine Tumors Treated With Lanreotide Depot
Wolin, E. M., Lowenthal, S. P., Fisher, G. A., Liyanage, N., Mirakhur, B., Pommier, R. F., … Vinik, A. I. (2017). Change in Patient-Reported Symptom Control in Patients With Neuroendocrine Tumors Treated With Lanreotide Depot. AMERICAN JOURNAL OF GASTROENTEROLOGY, 112, S652–S653. -
Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study.
Kardosh, A., Lichtensztajn, D. Y., Gubens, M. A., Kunz, P. L., Fisher, G. A., & Clarke, C. A. (2018). Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Pancreas, 47(8), 958–66. -
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., … Diaz, L. A. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. SCIENCE, 357(6349), 409–13. -
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel, M. E., Phan, A. T., Wolin, E. M., Mirakhur, B., Liyanage, N., Pitman Lowenthal, S., … Vinik, A. I. (2018). Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. The Oncologist. -
The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience.
Das, S., Pineda, G., Goff, L., Sobel, R., Berlin, J., & Fisher, G. (2018). The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience. Cancer Imaging : the Official Publication of the International Cancer Imaging Society, 18(1), 47. -
Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer.
Tummers, W. S., Miller, S. E., Teraphongphom, N. T., van den Berg, N. S., Hasan, A., Longacre, T. A., … Poultsides, G. A. (2019). Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. HPB : the Official Journal of the International Hepato Pancreato Biliary Association. -
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1802018. -
Pancreatic Adenocarcinoma, Version 1.2019
Tempero, M. A., Malafa, M. P., Chiorean, E. G., Czito, B., Scaife, C., Narang, A. K., … Zuccarino-Catania, G. (2019). Pancreatic Adenocarcinoma, Version 1.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(3), 203–10. -
Lanreotide for the Prolonged Control of Carcinoid Syndrome (CS) in Somatostatin Analog (SSA)-Naive or -Experienced Patients
Wolin, E., Fisher, G., Lowenthal, S. P., Mirakhur, B., Pommier, R., Shaheen, M., & Vinik, A. (2019). Lanreotide for the Prolonged Control of Carcinoid Syndrome (CS) in Somatostatin Analog (SSA)-Naive or -Experienced Patients. PANCREAS, 48(3), 455–56. -
A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors: ATrial of the ECOG-ACRIN Cancer Research Group (E2211)
Kunz, P. L., Catalano, P., Nimeiri, H. S., Fisher, G. A., Longacre, T. A., Suarez, C. J., … Benson, A. B. (2019). A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors: ATrial of the ECOG-ACRIN Cancer Research Group (E2211). PANCREAS, 48(3), 443. -
Unmet Needs in the Global NETs Patient Community From the Perspectives of Patients, Patient Advocates, and NET Health Professionals
Kolarova, T., Bouvier, C., Caplin, M., Conroy, S., Davies, P., Dureja, S., … Wiedenmann, B. (2019). Unmet Needs in the Global NETs Patient Community From the Perspectives of Patients, Patient Advocates, and NET Health Professionals. PANCREAS, 48(3), 442. -
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba, P., Sahoo, D., Paik, S., Guo, X., Yothers, G., Song, N., … Clarke, M. F. (2016). CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. The New England Journal of Medicine, 374(3), 211–22. -
Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method.
Goodman, K. A., Patton, C. E., Fisher, G. A., Hoffe, S. E., Haddock, M. G., Parikh, P. J., … Hoffman, K. E. (2015). Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. Practical Radiation Oncology, 6(3), 166–75. -
Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System.
Toesca, D. A., Jeffrey, R. B., von Eyben, R., Pollom, E. L., Poullos, P. D., Poultsides, G. A., … Chang, D. T. Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. Pancreas, 48(5), 622–28. -
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. JOURNAL OF CLINICAL ONCOLOGY, 37(12), 946-+. -
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors
Pavel, M. E., Phan, A. T., Wolin, E. M., Mirakhur, B., Liyanage, N., Lowenthal, S. P., … Vinik, A. I. (2019). Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. ONCOLOGIST, 24(4), 463–74. -
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
O'Reilly, E. M., Oh, D.-Y., Dhani, N., Renouf, D. J., Lee, M. A., Sun, W., … Philip, P. A. (2019). Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncology. -
Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer
Pumpalova, Y., Kozak, M. M., von Eyben, R., Kunz, P., Fisher, G., Chang, D. T., & Haraldsdottir, S. (2019). Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 10(4), 605–15. -
Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer
Tummers, W. S., Miller, S. E., Teraphongphom, N. T., van den Berg, N. S., Hasan, A., Longacre, T. A., … Poultsides, G. A. (2019). Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. HPB, 21(7), 883–90. -
Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients.
Das, S., Pineda, G., Berlin, J., Hemphill, B., Moslehi, J., Nohria, A., & Fisher, G. (2018). Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients. Journal of Oncology and Cancer Research, 2, 23–27. -
Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer.
Pumpalova, Y., Kozak, M. M., von Eyben, R., Kunz, P., Fisher, G., Chang, D. T., & Haraldsdottir, S. (2019). Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer. Journal of Gastrointestinal Oncology, 10(4), 605–615. -
Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System
Toesca, D. A. S., Jeffrey, R. B., von Eyben, R., Pollom, E. L., Poullos, P. D., Poultsides, G. A., … Chang, D. T. (2019). Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.
Leyden, S., Kolarova, T., Bouvier, C., Caplin, M. E., Conroy, S., Davies, P., … Hollander, R. (2019). Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
ROCKET: A randomized, multicenter phase 2 study of RRx-001+irinotecan versus regorafenib in 3rd/4th line colorectal cancer.
Reid, T. R., & Fisher, G. A. (2019). ROCKET: A randomized, multicenter phase 2 study of RRx-001+irinotecan versus regorafenib in 3rd/4th line colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients
O'Hara, M. H., O'Reilly, E. M., Rosemarie, M., Varadhachary, G., Wainberg, Z. A., Ko, A., … Vonderheide, R. H. (2019). A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. CANCER RESEARCH, 79(13). -
Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.
Shukla, N., Abrha, A., Longacre, T. A., Koff, R., Ford, J. M., Fisher, G. A., & Haraldsdottir, S. (2019). Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers. JOURNAL OF CLINICAL ONCOLOGY, 37(4). -
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., … Berlin, J. (2020). Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. The Oncologist. -
Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit.
Li, B., Jiang, Y., Li, G., Fisher, G. A., & Li, R. (2020). Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit. JCI Insight. -
Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., … Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27). -
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer.
Tsujikawa, T., Crocenzi, T., Durham, J. N., Sugar, E. A., Wu, A. A., Onners, B., … Le, D. T. (2020). Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.
Lu, G., van den Berg, N. S., Martin, B. A., Nishio, N., Hart, Z. P., van Keulen, S., … Poultsides, G. A. (2020). Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study. The Lancet. Gastroenterology & Hepatology. -
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients
Fisher, G. A., Lakhani, N. J., Eng, C., Hecht, J. R., Bendell, J. C., Philip, P. A., … Patnaik, A. (2020). A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, C. M., … Davidzon, G. (2020). Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience
Duan, H., Ninatti, G., Girod, B., Ferri, V., Guja, K., Song, H., … Aparici, C. M. (2020). Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)
Duan, H., Girod, B., Ninatti, G., Ferri, V., Kunz, P., Fisher, G., … Aparici, C. M. (2020). Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs). JOURNAL OF NUCLEAR MEDICINE, 61. -
Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford.
Abrha, A., Shukla, N. D., Hodan, R., Longacre, T., Raghavan, S., Pritchard, C. C., … Haraldsdottir, S. (2020). Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. JNCI Cancer Spectrum, 4(5), pkaa054. -
Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review.
Rahimy, E., Koong, A., Toesca, D., White, M. N., Panjwani, N., Fisher, G., … Pollom, E. (2020). Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review. Advances in Radiation Oncology, 5(6), 1188–96. -
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., … Vonderheide, R. H. (2021). CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet. Oncology, 22(1), 118–31. -
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., … Vonderheide, R. H. (2021). CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. LANCET ONCOLOGY, 22(1), 118–31. -
A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers.
Ma, W. W., Zhu, M., Lam, E. T., Diamond, J. R., Dy, G. K., Fisher, G. A., … Jimeno, A. (2021). A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. Cancer Chemotherapy and Pharmacology. -
A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
Lopez, J. S., Camidge, R., Iafolla, M., Rottey, S., Schuler, M., Hellmann, M., … Powles, T. (2020). A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. CANCER RESEARCH, 80(16). -
Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair deficient pancreatic cancer.
Tsang, E. S., Walker, E. J., Carnevale, J., Fisher, G. A., & Ko, A. H. (2021). Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair deficient pancreatic cancer. Immunotherapy. -
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
Shen, J., Lee, T. B., Hwang, J.-E., Choi, Y.-L., Lee, S.-H., Kim, H., … Bang, Y.-J. (2021). Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types. Journal of Clinical Oncology , 39. -
Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy.
Till, J. E., Abdalla, A., Bhagwat, N., Black, T. A., Wang, Z., Yee, S. S., … Carpenter, E. L. (2021). Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in-A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
Eads, J. R., Weitz, M., Catalano, P. J., Gibson, M. K., Rajdev, L., Khullar, O., … O'Dwyer, P. J. (2021). A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in-A trial of the ECOG-ACRIN Cancer Research Group (EA2174). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.
Whitman, J., Kardosh, A., Diaz, L., Fong, L., Hope, T., Onodera, C., … Bergsland, E. (2019). Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma. JCO Precision Oncology, 3, 1–7. -
MULTIOMIC BIOMARKER SIGNATURES IDENTIFY SUBSETS OF PATIENTS WHO MAY BENEFIT FROM EITHER NIVOLUMAB OR SOTIGALIMAB IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC PANCREATIC CANCER
Maurer, D., Yu, J. X., Sklodowski, K., Tognetti, M., Reiter, L., Bruderer, R., … Kitch, L. (2021). MULTIOMIC BIOMARKER SIGNATURES IDENTIFY SUBSETS OF PATIENTS WHO MAY BENEFIT FROM EITHER NIVOLUMAB OR SOTIGALIMAB IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC PANCREATIC CANCER. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Radiographic, Biochemical, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best?
Javadi, C., Chang, J., Forgo, E., Ahmad, M. U., Fisher, G. A., Chang, D. T., … Poultsides, G. A. (2022). Radiographic, Biochemical, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? ANNALS OF SURGICAL ONCOLOGY. SPRINGER. -
Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., & Mari Aparici, C. (2022). Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. The Oncologist. -
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padron, L. J., Maurer, D. M., O'Hara, M. H., O'Reilly, E. M., Wolff, R. A., Wainberg, Z. A., … Vonderheide, R. H. (2022). Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine. -
Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., … Aparici, C. M. (2022). Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Safety, Pharmacodynamic, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Subjects With Advanced Neuroendocrine Tumors
El-Rayes, B. F., Hendifar, A. E., Pant, S., Wilky, B. A., Reilley, M. J., Benson, A. B., … Tang, Z. (2022). Safety, Pharmacodynamic, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Subjects With Advanced Neuroendocrine Tumors. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz, P. L., Graham, N. T., Catalano, P. J., Nimeiri, H. S., Fisher, G. A., Longacre, T. A., … Benson, A. B. (2022). A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 101200JCO2201013. -
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Rajdev, L., Lee, J.-W., Libutti, S. K., Benson, A. B., Fisher, G. A., Kunz, P. L., … O'Dwyer, P. J. (2022). A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. Investigational New Drugs. -
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
Eads, J. R., Catalano, P. J., Fisher, G. A., Rubin, D., Iagaru, A., Klimstra, D. S., … O'Dwyer, P. J. (2022). Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.
Padron, L. J., Maurer, D. M., O'Hara, M. H., O'Reilly, E. M., Wolff, R. A., Wainberg, Z. A., … Vonderheide, R. H. (2022). Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across > 16 primary tumor types
Shen, J., Choi, Y.-L., Lee, T., Kim, H., Chae, Y. K., Dulken, B., … Ock, C.-Y. (2022). The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across > 16 primary tumor types. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving chemoimmunotherapy
Till, J. E., McDaniel, L., Pfeiffer, S. M., Maurer, D. M., Yu, J., Spencer, C., … Carpenter, E. L. (2022). Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving chemoimmunotherapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).
Kunz, P. L., Graham, N., Catalano, P. J., Nimeiri, H., Fisher, G. A., Longacre, T. A., … Benson, A. B. (2022). A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
EA2183: A phase III study of consolidative radiotherapy in patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma
Uboha, N. V., Graham, N., Rajdev, L., Gibson, M. K., Fisher, G. A., Lin, S. H., … O'Dwyer, P. J. (2022). EA2183: A phase III study of consolidative radiotherapy in patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.
Reid, T. R., Abrouk, N., Caroen, S., Oronsky, B., Stirn, M., Larson, C., … Fisher, G. (2022). ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer. Clinical Colorectal Cancer. -
Building a learning network to accelerate improvement in pancreas cancer care and outcomes: Canopy Cancer Collective
Herman, J. M., Stricker, C. T., Myers, S., Korah, B., Narang, A., Hacker-Prietz, A., … Margolis, P. (2022). Building a learning network to accelerate improvement in pancreas cancer care and outcomes: Canopy Cancer Collective. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation.
Nguyen, A. T., Berry, G. J., Witteles, R. M., Le, D. T., Wu, S. M., Fisher, G. A., & Zhu, H. (2022). Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation. JACC. CardioOncology, 4(5), 727–730. -
Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma.
King, D. A., Weiel, J. J., Reyes, R., Mills, M., Itchon, A., Fisher, G. A., … Suarez, C. J. (2023). Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma. JCO Precision Oncology, 7, e2200093. -
Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes.
Toesca, D. A., Susko, M., von Eyben, R., Baclay, J. R., Pollom, E. L., Jeffrey, R. B., … Chang, D. T. (2023). Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes. Annals of Surgical Oncology. -
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.
King, D. A., Smith, A. R., Pineda, G., Nakano, M., Michelini, F., Goedegebuure, S. P., … Kuo, C. J. (2023). Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates. JCO Precision Oncology, 7, e2100489. -
EXPLORATORY PLATFORM TRIAL TO EVALUATE IMMUNOTHERAPY COMBINATIONS WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC ADENOCARCINOMA (REVOLUTION)
Lyman, J., O'Reilly, E., Wainberg, Z., Fisher, G., Wolff, R., Ko, A., … Vonderheide, R. (2022). EXPLORATORY PLATFORM TRIAL TO EVALUATE IMMUNOTHERAPY COMBINATIONS WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC ADENOCARCINOMA (REVOLUTION). JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.
Stockton, S., Catalano, P., Cohen, S. J., Burtness, B. A., Mitchell, E. P., Dotan, E., … Benson, A. (2023). Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. The Oncologist. -
A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Fracasso, P. M., Fisher, G. A., Goodner, S. A., Beumer, J. H., Egorin, M. J., Fears, C. L., … Sikic, B. I. (2023). A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors. American Journal of Clinical Oncology. -
Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultsides, G., … Vitzthum, L. K. (2023). Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation. Annals of Surgical Oncology. -
Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report.
Zhang, V., Taparra, K., Fisher, G., Aparici, C., & Soltys, S. G. (2023). Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report. Cureus, 15(9), e45327. -
ASO Visual Abstract: Patterns of Recurrence after Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultsides, G., … Vitzthum, L. K. (2023). ASO Visual Abstract: Patterns of Recurrence after Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation. Annals of Surgical Oncology. -
KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer.
Aljehani, M. A., Bien, J., Lee, J. S., Fisher, G. A., & Lin, A. Y. (2023). KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer. JAMA Network Open, 6(11), e2345801. -
Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).
Lyman, J. P., Cabanski, C. R., Maddock, S., Wolff, R. A., Wainberg, Z. A., Ko, A. H., … O'Reilly, E. M. (2023). Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001+irinotecan vs. regorafenib plus irinotecan in third/fourth-line colorectal cancer.
Reid, T. R., Abrouk, N., Oronsky, B., Caroen, S., & Fisher, G. A. (2023). Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001+irinotecan vs. regorafenib plus irinotecan in third/fourth-line colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.
Shen, J., Choi, Y.-L. L., Lee, T., Kim, H., Chae, Y. K., Dulken, B. W., … Ock, C.-Y. Y. (2024). Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. Journal for Immunotherapy of Cancer, 12(2). -
Advancing Clinical Trial Equity through Integration of Telehealth and Decentralized Treatment.
Brown, E., Albert Fisher, G., Shelton, A., Chang, D. T., & Pollom, E. (2024). Advancing Clinical Trial Equity through Integration of Telehealth and Decentralized Treatment. JNCI Cancer Spectrum. -
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.
Till, J. E., McDaniel, L., Chang, C., Long, Q., Pfeiffer, S. M., Lyman, J. P., … Carpenter, E. L. (2024). Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nature Communications, 15(1), 5763. -
Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX).
Pollom, E. L., Fisher, G. A., Shelton, A., Johnson, T. P., Chen, C., Jackson, S., … Chang, D. T. (2024). Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Clinical and translational results from REVOLUTION cohorts A (nivolumab plus ipilimumab plus chemotherapy) and B (hydroxychloroquine plus ipilimumab plus chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.
O'Reilly, E. M., Wainberg, Z. A., Fisher, G. A., Wolff, R. A., Ko, A. H., O'Hara, M. H., … Vonderheide, R. H. (2024). Clinical and translational results from REVOLUTION cohorts A (nivolumab plus ipilimumab plus chemotherapy) and B (hydroxychloroquine plus ipilimumab plus chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Predicting rapid progression and overall survival in stage II-III pancreatic cancer using a CT-based radiomic signature.
Xu, Q., Toesca, D. A. S., Schueler, E., Jamalian, A., Alkim, E., Chang, D. T., … Itakura, H. (2024). Predicting rapid progression and overall survival in stage II-III pancreatic cancer using a CT-based radiomic signature. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Early results of a pancreas cancer learning health network: Canopy Cancer Collective.
Herman, J. M., Alyesh, A. Z., Korah, B., Narang, A., Deperalta, D., Lowy, A. M., … Stricker, C. T. (2024). Early results of a pancreas cancer learning health network: Canopy Cancer Collective. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Clinicopathological features and clinical outcomes in individuals with Krukenberg tumors of colorectal origin.
Bergstrom, C. P., Wang, C., King, D., Lin, A. Y., & Fisher, G. A. (2024). Clinicopathological features and clinical outcomes in individuals with Krukenberg tumors of colorectal origin. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
-
Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
- A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
- A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
- TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
- Telotristat Etiprate for Carcinoid Syndrome Therapy
Practice Locations
Gastrointestinal (GI) Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Gastrointestinal (GI) Cancer Program in Palo Alto
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(307 reviews)
Empathetic doctor, very kind.
I owe my life to Dr. George Fisher, Jr. and am grateful for his clinical expertise, medical advice, support and care.
I’m very grateful that Dr Fisher is in charge of my care.
Made everything understandable at my level
And was very personable.
Dr. Fisher and Dr. Glover are both wonderful doctors with a sense of humor and compassion!
He is a great human being and an awesome doctor!!! The best !!!
Dr. Fisher is always well-prepared and knowledgeable.
He has my complete confidence.
He is a good guy help out a lot
I feel that Dr. Fisher is the best doctor/oncologist that Stanford has. I thank him tremendously for the time and profession that he's given me.
Best in the business. Incredibly knowledgeable and comes prepared.
Outstanding physician in all respects.
Dr. Fisher explains my cancer case very clearly, listens to my issues and helps with solutions.
Dr. Fisher is very caring.
Dr. George Fisher is excellent doctor, with abundance of knowledge about my disease. He also is warm and personable and using different methods to help me.
Direct and helpful
Always cheerful, personable and extremely knowledgable.
Excellent care.
His the best
Dr George Fisher is one of the best Oncologists in the world.
I am proud and honored of having him as my oncologists.
I owe him my life.
Excellent Dr and amazing human being. Very personal. Knows how to explain things at a patient level.
Kudos.
He's a great doctor -- spends time providing options and information. Visits do not feel rushed as I've experienced with other providers (not at Stanford). I'm so glad I was referred to him.
Extremely helpful!
All was excellent
Dr. George Fisher is the best. I feel very lucky that he is my doctor.
Great to have doctor fisher on my side for my cancer treatment
Dr. Fisher is an incredibly talented and compassionate physician.
Dr. Fisher provided excellent care during my visit. He was well-prepared, answered all of my questions, and offered several treatment options. He also had great bedside manner and excellent communication .
Very straightforward and understandable.
Well informed, up on new research, warm, relational, remembers us, explains well, spells peculiar medication names.
He seems genuinely interested in me and my care.
I’m completely happy with appointment and appreciate Dr. Fisher who explained CT results and future options regarding treatments. He answered my questions completely and clearly! I very much appreciate Dr. Fisher! Thank you!
He is the best oncologist ever. I am so grateful and lucky that he is my doctor.
None..he is a GREAT doctor!!
Dr. Fisher is an outstanding physician, always kind, compassionate, and knowledgeable. I cannot imagine seeing anyone else.
Dr. Fisher is very polite and delivers his message in a very confident and professional manner.He listens to your questions and responds precise and to the point.I felt very comfortable talking with him.I was very satisfied with the video visit.
A great doctor who really took the time to answer all my questions and consider all possibilities for my care. I am very appreciative.
Awesome Doctor who highly recommend him!!
I like that Dr. Fisher is very direct and affable. He explained the road ahead, which helps me by reducing uncertainty. And he took time to answer questions. Excellent.
Very knowledgeable.
Like his style
Dr. Fisher was outstanding. He provided very helpful recommendations and explanations. He has a very friendly and empathetic demeanor, which I appreciated very much.
Very knowledgeable. Highly recommend.
Dr. Fisher is an excellent oncologist, well-supported by a knowledgeable and caring staff.
Compassionate
Listens to my questions
Dr Fisher is very thorough
Phenomenal, extremely talented and compassionate physician.
Thanks Dr. Fisher.
I very much appreciated Dr. Fisher Jr. and his team's efforts in offering an alternative to what I thought I had only one option. His warmth and caring came right through— as an oncologist, this helps the patient tremendously. Today I felt uplifted.
Thank you so much for your time energy and support. With so much pancreatic cancer in my family it’s a very scary experience and worry about my future, but feel like I am in good hands and trust Dr Fisher and Stanford with receiving the best possible care
Very friendly and helpful
Thank you Dr Fisher.
Knowledgeable and eager to help!
Didn’t hear anything new in term of treatment. Considering waster of time
Excellent and kind MD . Dr Fisher covered many topics in an easy to understand fashion
Great dr, feel privileged to have access to his expertise
Dr. Fisher and Dr. Patel were great and explained everything well and were easy to understand. Additionally they answered all of our questions clearly and concisely.
Great doctor. He has a great experience. Very gifted doctor.
Dr Fisher took time to thoroughly discuss my concerns and was very gracious and direct
Again, a better balance of video and in person visits would allow for a more confident understanding of his direction’s.
Incredible physician
Great job ðŸ‘
Great Doctor..
Maybe the best Doctor.
Excellent doctor, very knowledgeable and involving.
Dr. Fisher was aware of the issues my health situation has. He listened to my concerns and his observations and recommendations were understandable. He was kind and I appreciate the personalized responses to my questions.
Dr. Fisher is excellent at listening to and providing pertinent information. He is patient and encouraging. He and I discussed what needed to happen next and agreed on it.
The automated quiz asks inappropriate questions that I had to say no to because that is not how normal people communicate. Those topics were all adequately covered. Just not in the awkward stilted way that the automated quiz suggested it should be done. That is nonsense.
First rate MD clinician and researcher. I have known Dr Fisher for about 12 years and work with George frequently on PanCAN issues.
Has been excellent in treatment of my illness, along with the whole team there at Stanford Medical.
He is simply the best. He is deeply knowledgeable and is happy to talk at any level with the patient. He is also empathic and good humored. The world is lucky to have such as he.
Clearly very knowledgeable, and very helpful in advising us.
Enjoyed our discussion. Most helpful.
I feel very fortunate to have Dr. Fisher. The combination of clinical knowledge coupled with fantastic bedside manner is unmatched! Thank you.
He is great
Brilliant clinician and teacher, kind and respectful, listened carefully
Dr Fisher help me a whole lot so far I’m grateful to of him to be my my Dr
Did Fisher is excellent. He always takes time to hear what I have to say and has solutions for me. He is my favorite oncologist and I trust him.
excellent physician
He has always been very nice, and answers questions that I can understand, as I don’t have a medical background.
Dr Fisher is very pleasant to talk to he always answer questions that I ask him pertaining to my cancer
Outstanding physician
A terrific doctor and man.
Very friendly and knowledgable. The fellow was also nice. Because the fellow met with me first, I was able to talk out a lot of my concerns and get some feedback before my more limited time with Dr. Fisher.
Very professional and concerned. I am pleased with our relationship.
Dr Fisher is very professional and caring. He makes things extremely easy, especially when you don’t live in the area.
very patient oriented doctor,
I am honored of being his patient. I owe him my life. Kudos for a job well done.
Excellent doctor. He answered all questions clearly. We are in good hands.
Superb.
Great physician.
I am so fortunate to have such a reputed doctor looking at and advising on my case. I appreciate his time, insights, and recommendations so much.
First rate in every regard
Good communicator, empathetic, competent, good sense of urgency
Been working with George for a decade following pancreatic cancer
Excellent. Hands down an expert—if not the expert—in his field. Grateful to be his patient.
I have always felt a solid connection with Dr. Fisher and full confidence as well.
Exceptionally knowledgeable with a great bedside manner.
Dr. Fisher and Tita really spent quality time with me today. I was able to get my concerns and questions heard. Thank you!
Dr . Fisher is a very talented professional..
Very kind, very caring. Very attentive
For single tiny detail.
I believe he achieved most important goal in our life’s- he helped people to be happy…
Great Thank you
Respectfully
Thank you.
good
He was very patient in hearing and answering our questions.
I have had a great relationship with Dr Fisher Jr, I think he is a great doctor and a wonderful person.
Very easy to understand. Thank you.
I was extremely pleased with Dr. Fisher's highly informative care. He is a knowledgeable and experienced physician, who can be relied on to give the best medical advice to patients.
He knows so many of the doctors over here in Santa Cruz. That's warming. He understands that I'm ignorant and terrified and that I need. not be either. That's reassuring. And I always feel refreshed and positive after all my visits
Liked that he didn’t make me feel rushed. Explained everything in detail.
very kind and caring. It is a pleasure to know you have a great doctor caring for you!
Dr Fisher is very pleasant to talk I’m glad he is on the teams of Drs trying to cure my cancer
Thoughtful and clear in his communication with a sense of timeliness and promptness to initiate investigation of a potential treatment.
We good visit.
Very empathetic conversation.
Dr. Fisher is extremely professional and personable. The information he provided was clearly stated and appropriate to my level of understanding of my cancer and of relevant treatment options. I feel I'm able to make treatment decisions as a result of the information he provided, combined with what I already understood.
Dr. Fisher is a kind and caring person. He is honest and direct. He obviously is a highly knowledgeable specialist.
Very informative, took the time needed, friendly
very caring, knowledgeable and compassionate
He’s a good doctor with a sense of humor. He makes his patient at ease and you can easily opened up & ask questions regarding your illness.
Both of the doctors were kind and helpful
Dr. Fisher was very knowledgeable and provided clear path for treatment in future.
Kind, competent, top of his game. I feel very privileged to be his patient.
Very very helpful and informative.
Wonderful doctor who is both straight forward as well as empathetic
Dr. Fisher is a excellent doctor, clinician. His expertise, wisdom and care for his patients his clearly evident. Stanford is fortunate to have him, his patients grateful for his medical care.
George is an amazingly up-to-date physician re giving excellent second opinions on pancreatic cancer therapy, which was what I requested. Also quite compassionate.
He is wonderful
Dr Fisher is a very knowledgeable doctor with very good communication skills.
Incredibly compassionate and talented physician.
He’s the best!
I really appreciated Dr Fisher's expert knowledge and warm personality. We would like to contact Dr. Fisher in the future.
Excellent explanation and advice on my cancer situation.
Dr Fisher is a marvel. He made a difficult conversation a lot less difficult. He’s straightforward and professional while maintaining a good personal balance.
I can’t recommend him highly enough.
Enjoyed meeting my doctor in person.
Dr. Fisher got right to the point and explained next steps very clearly. He also gave me plenty of time to ask any questions I might have.
He was comforting and wonderful
Dr Fisher is wonderful. He had to explain something to me that he thought would be hard for me to understand. I understood quite well, and I don't think he dumbed it down too much...just enough.
He also told me he was having trouble getting a test result from my previous provider. When I recommended that he make use of the tissue that was available from the surgery I just had rather than waiting to use the results from biopsy sample, which was very small, he didn't miss a beat in agreeing with me.
George Fisher is an excellent and reasonable Oncology specialist that has a calm demeanor. He is thoughtful and takes my concerns seriously. He gives me useful, practical advice on how to manage my monitoring protocol. He is also resourceful in helping me to navigate Stanford's system for receiving, reading, and posting results and the challenge's caused by software programs used by outside labs and imaging facilities that are not compatible with Stanford's.
Thank you Dr. Fisher!
Informative and empathetic
Like his “style†and approach very much.
Easy to talk to. Provides good explanations
Excellent Doctor, I am pleased to have him as my oncologist.
Dr. Fisher and Tita have been very good to me. I do like to see them in person. The fact is that the video visits save me about $150, which is approximately what it costs me each time I drive to Palo Alto. So, I have to be positive about that!
George Fisher is one of the best oncologists in the USA.
I find Doctor Fisher, very competent, and straight forward, he seems concerned about my health and mind set.
Empathetic and informative physician
Doctor Fisher is the best!
Dr Fisher is the best. I have complete faith in him and I know I’m getting the best care possible. He’s got the perfect blend of professional demeanor and compassion.
Excellent Dr. I appreciate how thoroughly he understands my tests, their implications, and follow up actions. He is always well prepared for the visit.
I was happy with my visit. Dr Fisher was clear about what his recommendation for follow up was, and that it was available for me at Stanford, but I could also choose to continue with my local caregivers (to avoid driving 300 miles!)
Supper guy. Smart, thoughtful and articulae
I enjoyed the meeting and felt confident that we had a solid go-forward plan
He was very understanding in dealing with an 85 year old senior citizen.
I feel Dr Fisher is a great DR. and cares about his patients.I have been very pleased with the overall care I have received from him
I was seen first by an assistant and we discussed my aches and pains and fears. She.left and a few moments later Dr. FISHER Came in. I appreciate that. I don,t want to complain to Dr. Fisher. I want to listen and learn.
Easy to talk to (Tita is too) and listened to me
Excellent doctor, excellent care and attention.
A breath of fresh air! He offers his reasoned opinion without promoting an agenda (e.g., a doctor in the business of administering chemo is incentivized to administer chemo, even if the rationale is weak).
Very thankfull.
Dr. Fisher was excellent at explaining things and planning the next course of action.
He is very responsible. He attended our meeting even when he was sick. I very much appreciate his professional work. And this is the power of video conference. He could still see me remotely when he should be staying and resting in his home.
Please refer to the previous question. I will add that Dr. George Fisher treats a patient like he is the only one and is never in a hurry, explains medical procedures in laymen's terms, and responds thoughtfully to every inquiry from his patients. I could not have found a better oncologist anywhere else.
Thank you for the care and guidance these past 5+ years.
Dr Fisher is the best doctor, he has been taken care of me for last 4 years. He gave me all chemo treatments and supports along with my family. I would recommend Dr Fisher any time.
Expert in his field.
Dr. Fisher is an exceptional physician who is extremely knowledgeable, professional and caring. He has gone out of his way to make himself available and provide the care we needed. Thank you.
Easy to talk to and informative.
very confident and was a great consultant to me. I am grateful for his expertise
Dr. Fisher is a kind speaker, he informs me of what I need to do to keep on track with my health. I think highly of him and his staff.
Dr Fisher & his entire team are fantastic!
Dr. George is very responsible.
Dr.Fisher was very personable & took the time to make me feel comfortable
He is very knowledgeable and explains everything
He's great!
He is an excellent Doctor. I would like to see more communicating from Dr. Fisher and in person visit once in a while.
Dr Fisher is a very knowledgeable and caring doctor. I highly recommend him.
Doctor George Fisher is very good and competent physician./oncologist. He a nice person, very concern and compassionate to his patients.
Dr Fisher is a kind man.
I enjoyed my video visit with Dr. Fisher. I believe he answered my concerns and questions to the point and I appreciate his recommendations.
He listened to me while understanding me. I have a confidence in myself as a learner and a chooser that I didn't have before. And I've been seeing people and doing things for a whole year. I feel I can handle whatever will comes of my cancer. Dr. Fisher is a warm, friendly expert. Not from wit and charm but from experience. And from that experience he's made me to feel human and expert myself.
Great concerned doctor, kind and understanding.
I have confidence in Dr. Fisher and he is very personable. The latter quality has made a difference in the course of my treatment.
I recommend Dr. Fisher to anyone in the future
Dr Fisher is very caring and supportive providing the best in care.
Dr. Fisher’s bedside manor is very calming. He talks to you like a human being and does not go over your head with medical terms. I would recommend him to someone else.
I felt comfortable talking with him. His a good doctor.
He was very good, made me feel comfortable was easy to talk to ðŸ‘
I am completely confident in Dr Fisher’s competence as a medical expert. His empathetic nature and approach to the wholistic situation puts him at the top of the list as a complete and effective medical expert.
Dr Fisher gave me very thoughtful advise with 3 clear options, being careful to explain each one as he went along. He was patient and took the time to answer my questions.
Dr. Fisher was direct, clear, positive, knowledgable, listened well, asked pertinent questions, and was extremely helpful. I wish he was my doctor now.
Very easy to talk to...personable. Also covered my options thoroughly.
My experience to date has been excellent.
very personable
During my video visit with Dr. Fisher, I can say as patient, that I am in good hands. He is a great doctor/medical oncologist.
He provided a wealth of information during my consult. I know he is extremely busy so appreciated him reviewing my case and coming up with a plan for my treatments. I cannot say enough good things about Dr Fisher. I feel I am in very good hands with his care team.
I have complete confidence in Dr Fisher and his team. He’s wonderful
Excellent Doctor. Always gives details in easy to understand manner. Always answers my questions and conderns. Has cheerful attitude and gives you a good feeling after visit.
An excellent and knowledgeable physician
Excellent oncologist. Always a pleasure to meet with George ... just wish the circumstances were different ...
He is wonderful in appointmnets. Wish he provided more direct advice and check ins inbetween.
He is a wonderful doctor and wonderful man. I'm lucky to be under his care.
Thanks for the time today!
Excellent care, helped with any problems, always available, himself or his staff.
He listened to what I wanted to do, and had multiple plan options.
Excellent doctor, very knowledgeable and friendly. So fortunate to have him as my primary oncologist!
Dr. Fisher is a great oncologists and I feel ver confident he is the best one to care for my particular cancer.
I appreciate how straight forward Dr. Fisher is and how skilled he is as an oncologist.
Dr, Fisher answered all my questions in a pleasant manner.
He is a very nice and personable doctor. I feel very comfortable talking with him.
Dr Fisher made me feel comfortable. I felt optimistic that help was coming, that the medical team at Stanford was interested in timely treatment.
A wonderful supportive creative humane and yet humble doctor. I am grateful to God for having put him on my path.
We appreciate Dr Fisher and his team and the combined knowledge they all bring to my treatment program.
Appreciate very much that he is willing to take me as a patient. Appreciate his friendliness.
I think he is a wonderful doctor. Stanford is lucky to have him.
Very thankful for his expertise and the ability to connect remotely as I do not reside in the Bay Area.
The intake went smoothly with the Nurse Practioner Yuko, and we felt heard as she was able to convey our concerns to Dr. Fisher. Dr. Fisher listened to my update and allowed for amble questions as we discussed current symptoms and our future plan for treatment and MRI options.
Very caring and knowledgeable.
The BEST
He was professional, friendly, and made me feel comfortable talking with him. Same for Dr. Chen.
I appreciate Dr. Fisher's insight into my cancer condition and look forward to his guidance as we navigate through the chemotherapy process.
On time
Professional and courteous
Thank you Dr. Fischer. I am grateful to you and your staff for all that you do at Stanford to help people like me. You are very much appreciated.
Was very pleasant doctor with lost of knowledge
He is the very BEST!
Knowledgeable, carrying, kind, extremely positive, delivers a real hope and a light at the end of the tunnel. We really consider ourselves lucky and fortunate to be under his care.
Very warm and patient with all of our questions. Thank you for your time!
Dr. Fisher was very pleasant and answered my questions carefully.
Great to work with.
All is good thank you very much for your services from all the personnel.
Good experience.
Dr. Fischer IS WORTH the wait.
Hurried, late, short quick easy answers!
Dr. Fisher is amazing!!
BAD: Dr. Fisher promptly ended my appointment when inquiry about other treatments at Stanford. He got up and walked out. Very unprofessional!
If you need a great cancer doctor - go see Fisher.
I felt confident that the path I am on is right for me.
Exceptional care from both Dr. Fisher and his PA Ms. Tita. Tita was very courteous, took her time answered our questions explained and walked us through what to expect. As a family we all appreciate the time she took to answer our questions.
All excellent.
Dr. Fisher is not only a very good doctor but also a friendly and caring person.
Dr. Fisher is my hero! He's warm & caring, brilliant & a phenomenal doc. I feel very fortunate to have him quarter-backing my care.
Did not feel rushed.
Dr. Mou & Fisher were both very caring, knowledgeable & helpful. Much confidence in both.
Tita & Dr. Fisher are the BEST.
Very good. Thorough, thoughtful & professional.
Confidence increased with Dr. Fisher's breadth of knowledge. Very pleased.
We got the impression the care provider had very little to say concerning future treatment options, unless the patient is a candidate for clinical trial at Stanford.
Could not have had a better experience than I did on this initial visit with Dr. Fisher.
Dr. Fisher is great!
Dr. Fisher & his staff spent a great deal of time with me and were amazing, I am very grateful for the opportunity to meet w/him.
I have full trust in this care provider.
Dr. Fisher and his team have been my rock! I cannot imagine my life without them and cannot say enough in their praise.
Dr. Fisher was personable and professional.
Amazing knowledge and preparedness. I felt lucky to be seen by Dr. Fisher.
Spoke to Dr. Fisher who was very helpful and Dr. Chung who was also helpful in obtaining background information.
Dr. Fisher is the best example of a dr. or what a doctor should be always nice smiling caring I trust when he say something and he listen that what important. Wish they were all like him.
No bad experience.
I am very confident in Dr. Geo Fisher & staff.
Dr. Fisher and his assistant Dr. Mohana Roy are very nice and professional and warm welcome.
Dr. Fisher is not only an excellent oncologist, but also a very pleasant person to deal with. I am well pleased with his care.
Dr. Fisher is well regarded and seems to know his science well. I think he serves more patients than ideal. My biggest concern is that he is treating my cancer - not ME and often doesn't refer me to others or explain why not.
I have the deepest confidence imaginable and the very highest regard for every staff member with whom I have had contact!
The world would be a better place if all the dr. were a great as Dr. Fisher.
Blessed to be in the hands of this man.
I love Dr. Fisher & if the need arises I whole heartedly recommend him!
Nothing available at clinic at this time.
I have been a patient of Dr. Fisher for 9 years and have total confidence in him.
Dr. Fisher is an outstanding doctor - He has provided excellent care for several years and has a very pleasant personality.
MD fellow spent hour with me - excellent ...; MD Fisher - IS but reinforced fellow assessment.
Thorough.
Felt compassion.
Dr. Fisher was calling direct & had taken the time to "know about my issues. He has 'a way" that makes me feel that all will be OK his nurse was also very caring. He is amazing!!
Dr. Fisher made an effort and perhaps even saw me out of his regular visiting hours, nurse Jackie was the most attentive of RN's & so was Scott!!
Totally pleased with Dr. George Fisher & the staff surrounding him.
Off the scale great!
We have the utmost trust in Dr. Fisher!
Great Doc in George Fisher competent/caring/ a great person.
This visit was a little rushed.
I arrived feeling considerable concern about a pair of conflicting test results, and I departed with a sensible plan that left me feeling much relieved.
Dr. George Fisher is an excellent doctor. I've seen him for 14 years now -
Dr. Fisher seemed hurried.
Dr. George Albert Fisher is one of the kindest drs. that I know. He consistently takes the time to explain and lets you know what is going on and next steps if any. You can be very candid w/him and he is very honest w/your & your family.
Love Dr. Fisher call his fellow & trial people.
Dr. Fisher has taken excellent care of me.
After the clinical trial stopped working for my husband, Dr. Fisher pretty much told us that I cannot do anything about your condition anymore, so why don't you go to UCSF and ask them if they have clinical trials for you. He suggested for my husband to take Lonsurf in the meantime. Is this how Stanford treat their patients? No feeling of concern or compassion at all.
We came to Stanford for a 2nd opinion on a cancer diagnosis. Not only did Dr. Fisher give us a 2nd chemo to try (& hope) when he was I was taking notes he spelt the medication names and medical terminology for me.
Dr. Fisher is extraordinary in his handling of cancer patients like myself explaining everything in detail. He treats me as a family member and I rely on his expertise.
I so appreciate Dr. Fisher's willingness to take the time to talk with me, and still try to be on time for his other patients. I am willing to wait, because I know he takes this time with everyone.
outstanding doctor
Dr Fisher provided detailed information and answered my questions.
My doctor has always been extremely kind and compassionate. He shows true concern for my condition and always makes sure I have solutions or answers to all of my concerns. He is very knowledgeable about the medical condition I'm going through.
Dr. Fisher & his team provide great patient care!
With delight I recommend to other people.
Dr. George Fisher & staff are incredible. Stanford is excellent!
Very happy with Dr. Fisher and his staff especially Melissa Worman and nursing staff at 800 Walsh Rd. Research facility.
I trust that I am getting the best care possible, but I don't believe the doctor is being completely transparent with me. Last month, he proposed one course of treatment and this month he is proposing something different. It looked like I would be part of a clinical trial and now there are numerous reasons why I can't. I am very frustrated with the experience.
Dr. Fisher is a very kind doctor. He is also at the top of his field. How lucky to have such a wonderful doctor. He may be our life saver.
Wonderful man.
All good.
George Fisher is amazing - wonderful doctor and a very kind man
Dr Fisher is the best so caring and kind .
Dr George Albert Fisher and his team consistently provide information updates for the care and treatment of myself
Would like written explanation of decision rather than quick phone call. Decision was not made at time of consultation and no follow-up appointment.
I have referred MANY patients to Dr. Fisher, they all think he is the greatest - and he is.
Dr. Fisher appears over whelmed by patient care load. Very upset he did not discuss test results.
Always a pleasure to meet w/George Fisher.
An amazing experience - Dr. Fisher is a world leader in treatment of my condition, and spent a long time in evaluating & explaining my problem.
I wasn't given instructions for when to follow up with Dr. Fisher for my next appointment.
Excellent staff.
Excellent!
Wonderful dr.
Dr. Fisher was excellent.
Dr. Fisher is wonderful! Kind, patient, and knowledgeable! Thorough, clear in communication, listens well and shows compassion.
Dr. Fisher sat with me to demonstrate the findings on the CT images -> outstanding.
Dr. knew it was a 4 hr. drive & took trip in severe pain only to be told bluntly there was no hope. Very horrible experience even if it was true no feelings or care shown.
Very good -
Dr. Fisher and his staff always care about me and my condition - I feel like more than just another patient.
Why was I in so much pain? No answer.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records